Anti-Proteinuric Effect of Sulodexide in Immunoglobulin A Nephropathy.
10.3349/ymj.2011.52.4.588
- Author:
Kitae BANG
1
;
Ho Jun CHIN
;
Dong Wan CHAE
;
Kwon Wook JOO
;
Yon Su KIM
;
Suhnggwon KIM
;
Kyung Don JU
;
Hwajung KIM
;
Curie AHN
;
Kook Hwan OH
Author Information
1. Department of Internal Medicine, Eulji University of Medicine, Daejeon, Korea.
- Publication Type:Original Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
- Keywords:
IgA nephropathy;
sulodexide;
proteinuria
- MeSH:
Adult;
Anticoagulants/*therapeutic use;
Double-Blind Method;
Female;
Glomerulonephritis, IGA/complications/*drug therapy;
Glycosaminoglycans/*therapeutic use;
Humans;
Male;
Middle Aged;
Proteinuria/complications/*drug therapy
- From:Yonsei Medical Journal
2011;52(4):588-594
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We conducted a multi-center randomized double-blind study to determine the effects of 6-month therapy with sulodexide on urinary protein excretion in patients with idiopathic Immunoglobulin A (IgA) nephropathy. MATERIALS AND METHODS: A total of seventy-seven patients participated in the study. They were randomly allocated to one of three groups: sulodexide 75 mg or 150 mg daily or the placebo for 6 months. The primary end point was the achievement, at 6 months, of at least 50% reduction in urine protein/creatinine ratio (UPCR) from the baseline value. RESULTS: At 6 months, the primary end point was achieved by 12.5% of the patients assigned to the placebo, 4.0% of the patients assigned to sulodexide 75 mg daily and 21.4% of those assigned to 150 mg (p=0.308). Treatment with sulodexide 150 mg daily for 6 months significantly reduced log UPCR from 6.38+/-0.77 at baseline to 5.98+/-0.94 at 6 months (p=0.045), while treatment with sulodexide 75 mg daily and placebo did not. CONCLUSION: A 6-month treatment with sulodexide did not achieve 50% reduction of urinary protein excretion in IgA nephropathy patients, but showed a tendency to increase the time-dependent anti-proteinuric effect. Therefore, long-term clinical trials on a larger scale are warranted to elucidate the hypothesis that sulodexide affords renal protection in IgA nephropathy patients.
